ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: AXL overexpression has been linked to Imatinib-resistance in gastrointestinal stromal tumors [42], Nilotinib-resistance in CML [43] and Lapatinib-resistance in HER-2 positive breast tumor cells [44].